Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe

Purpose of review Despite the use of currently available lipid-lowering therapies, a significant proportion of patients with severe hypercholesterolaemia do not reach treatment goals and consequently remain at increased risk for cardiovascular disease (CVD). On the basis of clinical experience, these patients tend to have the most severe forms of familial hypercholesterolaemia or markedly elevated LDL cholesterol (LDL-C) levels but are unable to tolerate statin therapy. Recent findings LDL apheresis is currently the best treatment option (or treatment rescue) to bring these patients closer to therapeutic LDL objectives, and has been shown to reduce the risk of CVD along with LDL-C levels. However, criteria for LDL apheresis eligibility and the percentage of patients receiving treatment vary widely from country to country across Europe. Despite the proven benefits of LDL apheresis, access to this procedure remains limited because of its high cost and low availability, reflecting inherent limitations of this treatment modality. Summary There is a need to both better define the patient population eligible for LDL apheresis and to create unified European guidelines governing the use of apheresis. In addition to improving access to apheresis where appropriate, new therapies are needed to further decrease LDL-C and reduce the ongoing CVD risk in patients with severe hypercholesterolaemia.

[1]  V. Armstrong,et al.  Low‐Density Lipoprotein Apheresis Decreases Ferritin, Transferrin and Vitamin B12, Which May Cause Anemia in Serially Treated Patients , 2010, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[2]  J. Kastelein,et al.  Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. , 2010, Atherosclerosis.

[3]  A. Marais,et al.  Efficacy criteria and cholesterol targets for LDL apheresis. , 2010, Atherosclerosis.

[4]  S. Bornstein,et al.  Cardiovascular events in patients with increased lipoprotein (a) - retrospective data analysis in an outpatient department of lipid disorders. , 2009, Atherosclerosis. Supplements.

[5]  K. Harre,et al.  Indication and implementation of lipidapheresis, rheopheresis, or immunoadsorption (lessons learnt from Germany's largest apheresis center). , 2009, Atherosclerosis. Supplements.

[6]  R. Collins,et al.  Genetic variants associated with Lp(a) lipoprotein level and coronary disease. , 2009, The New England journal of medicine.

[7]  Stephen Kaptoge,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[8]  P. Mehta,et al.  Low-density lipoprotein apheresis as a treatment option for hyperlipidemia , 2009, Current treatment options in cardiovascular medicine.

[9]  Børge G Nordestgaard,et al.  Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. , 2009, JAMA.

[10]  J. Schulz-Menger,et al.  Single Lipoprotein Apheresis Session Improves Cardiac Microvascular Function in Patients With Elevated Lipoprotein(a): Detection by Stress/Rest Perfusion Magnetic Resonance Imaging , 2009, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[11]  R. Beigel,et al.  Homozygous familial hypercholesterolemia: Long term clinical course and plasma exchange therapy for two individual patients and review of the literature , 2009, Journal of clinical apheresis.

[12]  D. Rader,et al.  Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. , 2008, The American journal of cardiology.

[13]  J. Witteman,et al.  Efficacy of statins in familial hypercholesterolaemia: a long term cohort study , 2008, BMJ : British Medical Journal.

[14]  S. Humphries,et al.  Familial hypercholesterolaemia: summary of NICE guidance , 2008, BMJ : British Medical Journal.

[15]  G. Thompson.  Recommendations for the use of LDL apheresis. , 2008, Atherosclerosis.

[16]  J. Schlienger,et al.  Low‐density Lipoprotein Apheresis in Children With Familial Hypercholesterolemia: Follow‐up to 21 Years , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[17]  G. Francis,et al.  Vascular Calcifications in Homozygote Familial Hypercholesterolemia , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[18]  A. Pottle,et al.  Is there a place for LDL-apheresis in the management of raised cholesterol? , 2008 .

[19]  J. Kastelein,et al.  Statin Treatment in Children With Familial Hypercholesterolemia: The Younger, the Better , 2007, Circulation.

[20]  P. Moriarty.  LDL-apheresis therapy , 2006, Current treatment options in cardiovascular medicine.

[21]  P. Carlier,et al.  Hypercholesterolemia and LDL Apheresis , 2005, The International journal of artificial organs.

[22]  W. Frishman,et al.  Nonpharmacologic Approaches for the Treatment of Hyperlipidemia , 2005, Cardiology in review.

[23]  C. Gibson,et al.  Optimal Lipid Modification: The Rationale for Combination Therapy , 2005, Vascular health and risk management.

[24]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice , 2004 .

[25]  H. Büller,et al.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study , 2004, JAMA.

[26]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[27]  F. Civeira,et al.  Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. , 2004, Atherosclerosis.

[28]  Jonathan D. Cohen,et al.  Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. , 2003, The Journal of clinical investigation.

[29]  J. Kastelein,et al.  Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia , 2003, Journal of internal medicine.

[30]  E. Sijbrands,et al.  Low-Density Lipoprotein Receptor Gene Mutations and Cardiovascular Risk in a Large Genetic Cascade Screening Population , 2002, Circulation.

[31]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[32]  S. Piñeros,et al.  Frequency of serum low-density lipoprotein cholesterol measurement and frequency of results < or=100 mg/dl among patients who had coronary events (Northwest VA Network Study). , 2001, The American journal of cardiology.

[33]  B. Stegmayr,et al.  Adverse events and problems in therapeutic hemapheresis. A report from the Swedish registry. , 2001, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[34]  G. Taylor,et al.  Determinants of Variable Response to Statin Treatment in Patients With Refractory Familial Hypercholesterolemia , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[35]  M. Trip,et al.  Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial , 2001, The Lancet.

[36]  P. Benlian.  Genes of Lipoprotein Metabolism , 2001 .

[37]  L. Iacoviello,et al.  Familial hypercholesterolaemia. , 2001, Lancet.

[38]  M. V. van’t Hof,et al.  The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. , 2000, Atherosclerosis.

[39]  T. Pearson,et al.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. , 2000, Archives of internal medicine.

[40]  Sidney C. Smith,et al.  Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. , 1999, The American journal of cardiology.

[41]  H. Mabuchi,et al.  Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia , 1998 .

[42]  P. Nihoyannopoulos,et al.  Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia , 1998, Heart.

[43]  H. Mabuchi,et al.  Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. , 1998, The American journal of cardiology.

[44]  Clare,et al.  Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. , 1997, Journal of lipid research.

[45]  G. Thompson.  What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease? , 1997, Atherosclerosis.

[46]  A. Soutar,et al.  Characterization of mutations in the low density lipoprotein (LDL)-receptor gene in patients with homozygous familial hypercholesterolemia, and frequency of these mutations in FH patients in the United Kingdom. , 1996, Journal of lipid research.

[47]  T. Risler,et al.  Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. , 1994, Journal of lipid research.

[48]  A. Stalenhoef,et al.  ACE inhibitors and LDL-apheresis with dextran sulphate adsorption , 1992, The Lancet.

[49]  H. Hobbs,et al.  Molecular genetics of the LDL receptor gene in familial hypercholesterolemia , 1992, Human mutation.

[50]  T. Kita,et al.  Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia. , 1983, The New England journal of medicine.